Skip to main content

Spectrum of anti-myelin oligodendrocyte glycoprotein antibody (MOG-Ab)-associated diseases: an Indian perspective


Myelin oligodendrocyte glycoprotein antibody (MOG-Ab) is involved in the pathogenesis of central nervous system (CNS) demyelination disorders. We aimed to explore the spectrum of MOG-Ab-associated diseases in eastern India. A single-center, prospective observational study was done over a period of 2 years in a tertiary care hospital of eastern India. Patients with CNS demyelination disorders who tested positive for MOG-Ab using live cell-based assay were included in the study; while, those with age less than 1 year, documented preexisting CNS structural lesions, developmental delays or diagnosed multiple sclerosis were excluded. Demographic profile, clinical spectrum, disease course, radiological features as well as response to treatment were analyzed among included patients. Twenty MOG-Ab-positive patients were included (M:F 1:1.85). The median age of symptom onset was 10.5 years. The median follow-up of patients was 13 months. Acute disseminated encephalomyelitis (ADEM) was the commonest presentation at first attack (55%), followed by optic neuritis (ON) (45%). Patients with ADEM had a significantly lower age at first attack (p = 0.025). Monophasic and relapsing disease courses were seen in 45% and 55% patients, respectively. While all patients with only ADEM had a monophasic course, 77.8% with ON had a relapsing course. Among patients who presented with isolated transverse myelitis, 75% had a monophasic course and all had disease confined to the spinal cord. Good response to corticosteroids was seen in majority of participants. Second-line drugs were needed in 55% patients, rituximab being the commonest second-line agent used. 35% patients had significant disability (EDSS > 4) at last follow-up. MOG-Ab-associated diseases have diverse clinical phenotypes characterized by age-dependent pattern-specific courses.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5


  1. Ramanathan S, Dale RC, Brilot F (2016) Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev 15(4):307–324.

    Article  PubMed  CAS  Google Scholar 

  2. Duignan S, Wright S, Rossor T, Cazabon J, Gilmour K, Ciccarelli O et al (2018) Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes. Dev Med Child Neurol 60(9):958–962.

    Article  PubMed  Google Scholar 

  3. Dos Passos GR, Oliveira LM, da Costa BK et al (2018) MOG-IgG-associated optic neuritis, encephalitis, and myelitis: lessons learned from neuromyelitis optica spectrum disorder. Front Neurol 9:217

    Article  Google Scholar 

  4. Pandit L, Mustafa S, Nakashima I, Takahashi T, Kaneko K (2018) MOG-IgG-associated disease has a stereotypical clinical course, asymptomatic visual impairment and good treatment response. Mult Scler J Exp Transl Clin 4(3):2055217318787829

    PubMed  PubMed Central  Google Scholar 

  5. Reindl M, Waters P (2019) Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol 15(2):89–102

    Article  CAS  Google Scholar 

  6. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162–173

    Article  Google Scholar 

  7. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452

    Article  CAS  Google Scholar 

  8. Probstel AK, Rudolf G, Dornmair K, Collongues N, Chanson JB, Sanderson NS, Lindberg RL, Kappos L, de Seze J, Derfuss T (2015) Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflamm 8(12):46.

    Article  CAS  Google Scholar 

  9. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hümmert MW, Ringelstein M, Trebst C, Winkelmann A, Schwarz A, Buttmann M, Zimmermann H, Kuchling J, Franciotta D, Capobianco M, Siebert E, Lukas C, Korporal-Kuhnke M, Haas J, Fechner K, Brandt AU, Schanda K, Aktas O, Paul F, Reindl M, Wildemann B, Neuromyelitis Optica Study Group (NEMOS) (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflamm 13(1):280.

    Article  CAS  Google Scholar 

  10. Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J et al (2014) Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 71(3):276–283

    Article  Google Scholar 

  11. Konuskan B, Yildirim M, Gocmen R, Okur TD, Polat I, Kilic H et al (2018) Retrospective analysis of children with myelin oligodendrocyte glycoprotein antibody-related disorders. Mult Scler Relat Disord 26:1–7.

    Article  PubMed  Google Scholar 

  12. Pandit L, Sato DK, Mustafa S, Takahashi T, D'Cunha A, Malli C, Sudhir A, Fujihara K (2016) Relapsing optic neuritis and isolated transverse myelitis are the predominant clinical phenotypes for patients with antibodies to myelin oligodendrocyte glycoprotein in India. Mult Scler J Exp Transl Clin 24(2):2055217316675634.

    Article  Google Scholar 

  13. Fernandez-Carbonell C, Vargas-Lowy D, Musallam A, Healy B, McLaughlin K, Wucherpfennig KW, Chitnis T (2016) Clinical and MRI phenotype of children with MOG antibodies. Mult Scler. 22(2):174–184. 2015 Jun 3

    Article  PubMed  CAS  Google Scholar 

  14. Mao L, Yang L, Kessi M, Fang H, Zhang C, Liwen W (2019) Myelin oligodendrocyte glycoprotein (MOG) antibody diseases in children in central South China clinical features, treatments, influencing factors, and outcomes. Frontiers Neurol 10:1–11

    Article  Google Scholar 

  15. Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A et al (2017) Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain 140(12):3128–3138.[published correction appears in Brain. 2018 Apr 1;141(4):e31)]

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Jasodhara Chaudhuri.

Ethics declarations

Conflict interest

The author(s) declare(s) that there is no conflict of interest.

Ethical standards

We would like to state that our study was approved by appropriate Ethics Committee according to the International standards and we declare no authors did any intervention involving animals or humans here.

Informed consent

Written informed consent has been taken from the patients for participation in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chaudhuri, J., Biswas, T., Ganguly, G. et al. Spectrum of anti-myelin oligodendrocyte glycoprotein antibody (MOG-Ab)-associated diseases: an Indian perspective. Acta Neurol Belg 121, 927–931 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • Myelin oligodendrocyte glycoprotein
  • Encephalomyelitis
  • Transverse myelitis
  • Optic neuritis